Malaria: Epidemiology Forecast to 2027

2018-11-27
Price :
Published : Nov-2018
No. of Pages : 43

Malaria: Epidemiology Forecast to 2027

Summary

Malaria is a vector-borne disease caused by parasites of the genus Plasmodium. Malaria is transmitted through the bite of the female Anopheles mosquito. Upon infecting a new human host, parasites first travel to liver cells and eventually infect erythrocytes (red blood cells). Once erythrocytes have been infected, patients may exhibit symptoms such as fever, headache, and chills. However, some patients exhibit no symptoms. If left untreated, malaria can progress to a severe form that results in cerebral malaria, anemia, respiratory distress, kidney failure, and possibly death.

GlobalData epidemiologists provide a 10-year epidemiological forecast for confirmed incident cases and confirmed deaths from malaria segmented by sex and age in these markets. This report also forecasts confirmed cases segmented by Plasmodium species, P. falciparum cases with K13 propeller mutations, and seroprevalence of Plasmodium infection in pregnant women.

In 2017, there were 33,158,385 confirmed incident cases of malaria in the 6MM. The DRC had the most cases with 15,915,007, while Indonesia had the fewest with 194,913. The number of confirmed cases in the 6MM is expected to grow to 39,960,547 by 2027, for an Annual Growth Rate (AGR) of 2.05%. In 2017, there were 49,490 confirmed deaths from malaria in the 6MM. The DRC had the most confirmed deaths with 38,938, while Indonesia had the fewest with 182. The number of confirmed deaths from malaria in the 6MM is expected to grow to 59,810 in 2027, for an AGR of 2.09%.

Scope

– The Malaria Epidemiology Forecast Report provides an overview of the risk factors and global trends of Malaria in the six major markets (6MM: the Democratic Republic of the Congo [DRC], Ghana, Kenya, Nigeria, India, and Indonesia).
– This report also includes a 10-year epidemiological forecast for confirmed incident cases and confirmed deaths from malaria segmented by sex and age in these markets. This report also forecasts confirmed cases segmented by Plasmodium species, P. falciparum cases with K13 propeller mutations, and seroprevalence of Plasmodium infection in pregnant women.
– The malaria allergy epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

The Malaria Epidemiology Forecast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global malaria market.
– Quantify patient populations in the global malaria market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for malaria therapeutics in each of the markets covered.
– Understand magnitude of malaria population by mutations.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Digital Therapeutics and Their Impact on Healthcare

Digital Therapeutics and Their Impact on Healthcare Summary Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions. This report provides an overview of cur......
$7995

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products Summary An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
$6995

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends – Q1 2019

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019 Summary GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
$1500

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Italy

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Dental Caries Global Clinical Trials Review, H1, 2019

Dental Caries Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dental Caries Global Clinical Trials Review, H1, 2019" provides an overview of Dental Caries clinical trials scenario. This report provides top line data relating to the clinical trials on Dental Caries. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Duchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2019

Duchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Duchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2019" provides an overview of Duchenne Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary dat......
$2500

Diabetic Gastroparesis Global Clinical Trials Review, H1, 2019

Diabetic Gastroparesis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diabetic Gastroparesis Global Clinical Trials Review, H1, 2019" provides an overview of Diabetic Gastroparesis clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Gastroparesis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Dyspepsia Global Clinical Trials Review, H1, 2019

Dyspepsia Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dyspepsia Global Clinical Trials Review, H1, 2019" provides an overview of Dyspepsia clinical trials scenario. This report provides top line data relating to the clinical trials on Dyspepsia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019" provides an overview of Diffuse Large B-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprie......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy